Back to top

gene-editing: Archive

Zacks Equity Research

Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why

Sana Bio (SANA) rallies 105% after the company reports encouraging pipeline progress with its candidates, SC291 and SC262, for oncology and autoimmune indications.

PBYINegative Net Change ADMAPositive Net Change ACADNegative Net Change SANANegative Net Change

Zacks Equity Research

Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up

Solid Biosciences (SLDB) stock rises after the FDA grants the orphan drug designation to the company's novel gene-therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.

RHHBYNegative Net Change SRPTPositive Net Change PBYINegative Net Change SLDBPositive Net Change